Paolo G. Nuciforo
object(WP_Post)#5025 (24) {
["ID"]=>
int(966)
["post_author"]=>
string(1) "3"
["post_date"]=>
string(19) "2018-12-05 11:24:51"
["post_date_gmt"]=>
string(19) "2018-12-05 11:24:51"
["post_content"]=>
string(18) "[flsSpeakersModal]"
["post_title"]=>
string(17) "Paolo G. Nuciforo"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(16) "paolo-g-nuciforo"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2018-12-20 11:14:16"
["post_modified_gmt"]=>
string(19) "2018-12-20 11:14:16"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(64) "https://www.bcnmicrobiome.com/?post_type=fls-speakers&p=966"
["menu_order"]=>
int(0)
["post_type"]=>
string(12) "fls-speakers"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
Nuciforo, Paolo G.
Vall d'Hebron Institute of Oncology. Barcelona, Spain.
Paolo Nuciforo, MD, PhD, board certified Pathologist, is the Principal Investigator of the Molecular Oncology group at Vall d`Hebron Institute of Oncology (VHIO). He has 15+ years of experience in oncology translational medicine and drug development both in academic and pharmaceutical environment. He co-authored over 80 publications in peer-reviewed journals with a main focus on discovery and validation of novel biomarkers using tissue-based technologies. During the last two years, he has been working in deciphering the impact of Fusobacterium nucleatum infection in colorectal cancer evolution and in developing in situ visualization approaches to establish the invasive capabilities of microbes which could be crucial in more precisely identifying those patients who would be most likely to benefit from treatments targeting the cancer-associated microbiota.
